Omeros Corporation (NASDAQ:OMER) announced positive results from a Phase 2 clinical trial evaluating the effects of a peroxisome proliferator-activated receptor (PPAR)-gamma agonist in patients …
In a research report published Monday, Maxim analyst Jason Kolbert reiterated a Buy rating on shares of Omeros Corporation (NASDAQ:OMER) with a price target of …
Investors in Omeros Corporation (NASDAQ:OMER) should be smiling from ear to ear today after the drug maker announced positive data from its Phase 2 …
Omeros Corporation (NASDAQ:OMER) announced results from its OMS721 complement program. OMS721 is Omeros’ lead antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2).
Omeros Corporation (NASDAQ:OMER) shares tumbled nearly 12% today, after the company announced a $40-million underwritten public offering of its common stock at a …
Omeros Corporation (NASDAQ:OMER) announced results from its OMS906 complement program. OMS906 is Omeros’ lead antibody targeting mannan-binding lectin-associated serine protease-3 (MASP-3).
Omeros Corporation (NASDAQ:OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications …
Omeros Corporation (NASDAQ:OMER) announced that it has received scientific advice from the European Medicines Agency (EMA) in connection with the company’s OMS721 Phase 3 …
Omeros Corporation (NASDAQ:OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan …
Omeros Corporation (NASDAQ:OMER) announced that it has entered into an amendment to its existing credit facility with Oxford Finance LLC (“Oxford”) and East West …
